184 related articles for article (PubMed ID: 36562384)
1. Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion.
Velez BC; Petrella CP; DiSalvo KH; Cheng K; Kravtsov R; Krasniqi D; Krucher NA
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562384
[TBL] [Abstract][Full Text] [Related]
2. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
3. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Migita T; Narita T; Nomura K; Miyagi E; Inazuka F; Matsuura M; Ushijima M; Mashima T; Seimiya H; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y
Cancer Res; 2008 Oct; 68(20):8547-54. PubMed ID: 18922930
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
5. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
[TBL] [Abstract][Full Text] [Related]
6. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
7. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
8. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.
Ismail A; Doghish AS; E M Elsadek B; Salama SA; Mariee AD
Steroids; 2020 Aug; 160():108656. PubMed ID: 32439410
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.
Rencuzogulları O; Yerlikaya PO; Gürkan AÇ; Arısan ED; Telci D
J Cell Biochem; 2020 Jan; 121(1):508-523. PubMed ID: 31264276
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
13. ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.
Huang SS; Tsai CH; Kuo CY; Li YS; Cheng SP
Endocrine; 2022 Oct; 78(1):85-94. PubMed ID: 35761130
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPKα signaling pathway.
Liu W; Liu M; Xiong H; Xia L; Yang Q; Chen M; Cai Y; Li S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109392. PubMed ID: 36461594
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
17. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
18. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
19. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
20. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Xin M; Qiao Z; Li J; Liu J; Song S; Zhao X; Miao P; Tang T; Wang L; Liu W; Yang X; Dai K; Huang G
Oncotarget; 2016 Jul; 7(28):44252-44265. PubMed ID: 27317765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
